Aaron T. Gerds, MD, MS / John Mascarenhas, MD - Shaping Modern Management of Myelofibrosis: Guidance on the Conjunction of Targeted Therapy and AlloHCT

Go online to PeerView.com/SDA860 to view the activity, download
slides and practice aids, and complete the post-test to earn
credit. Are you prepared to develop personalized treatment plans
for your patients with myelofibrosis (MF) that incorporate the
latest therapeutic options, including JAK inhibitors, targeted
strategies, and HCT? Find out in this new PeerView CME activity,
featuring two experts who will use case-based clinical discussions
to illustrate how they manage MF with the individual patient in
mind. They will use these cases to discuss eligibility for HCT and
the need for pre-HCT therapy based on disease risk factors; use of
JAK inhibitor in non-HCT settings; practical dosing and safety
management considerations; and the emergence of novel targeted and
combinatorial strategies in the MF setting. Watch this informative
update on personalized care for patients with MF! Upon completion
of this activity, participants should be better able to: Discuss
patient- and disease-related features of MF that inform prognosis
and guide the selection of JAK inhibitors, other targeted
strategies, and HCT; Summarize efficacy and safety data surrounding
the use of JAK inhibitors, novel targeted strategies, and
innovative combination regimens in MF across the therapeutic
continuum; and Develop treatment plans that incorporate JAK
inhibitors and other novel therapies to manage MF in HCT and
non-HCT settings